Assessment of Physician's Knowledge of Potential Drug-Drug Interactions: An Online Survey in China

被引:11
|
作者
Yuan, Jing [1 ,2 ]
Shen, Chunying [1 ,2 ]
Wang, Chengnan [1 ,2 ]
Shen, Gang [3 ]
Han, Bing [1 ,2 ]
机构
[1] Fudan Univ, Minhang Hosp, Shanghai, Peoples R China
[2] Fudan Univ, Sch Pharm, Dept Clin Pharm, Shanghai, Peoples R China
[3] Minhang Dist Cent Hosp, Dept Neurosurg, Shanghai, Peoples R China
关键词
drug-drug interaction; PDDI; adverse drug event; survey; knowledge; medication;
D O I
10.3389/fmed.2021.650369
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Drug interactions are the most common preventable cause of adverse drug reaction, which may result in drug toxicity or undesired therapeutic effect with harmful outcomes to patients. Given the rising use of combination therapies, the main objectives of this study were to estimate the degree to which physicians can identify potential drug-drug interactions (PDDIs) correctly and to describe the common source of information used by physicians when they need to check PDDIs. Methods: A cross-sectional survey utilizing a self-administered online questionnaire was conducted among physicians in China. Participants were asked to classify 20 drug pairs as "no interaction," "may be used together with monitoring," "contraindication," and "not sure." We also collected data on the physician's source of information and altitude toward the PDDIs. An ordinary least square regression model was performed to investigate the potential predictors of PDDI knowledge. Results: Eligible questionnaires were obtained from 618 physicians. The respondents classified correctly 6.7 out of 20 drug pairs, or 33.4% of the drug interactions investigated. The number of drug pairs recognized by respondents was ranged from 0 to 16. The percentage of physicians who recognized specific drug pairs ranged from 8.3% for no interactions between conjugated estrogens and raloxifene, to 64.0% for the interaction between dopamine and phenytoin. When the respondents want to check PDDI information, the most commonly used source of information was package inserts (n = 572, 92.6%), followed by the Internet or mobile Apps (n = 424, 68.6%), consultation with clinical pharmacists (n = 384, 62.1%), medical textbooks (n = 374, 60.5%), knowledge base in Chinese (n = 283, 45.8%), and other physicians (n = 366, 59.2%). In the multiple regression analysis, the significant predictors of a higher number of recognized drug pairs were years of practice and altitudes toward PDDIs. Conclusion: In this online survey accessing physician's ability to detect PDDIs, less than half of the drug pairs were recognized, indicating unsatisfactory level of knowledge about the clinically significant drug interactions. Continuing education and accessible electronic database can help physicians detecting PDDIs and improve drug safety.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Potential drug-drug interactions in hospitalised haematological patients
    Fernandez de Palencia Espinosa, Ma Angeles
    Diaz Carrasco, Ma Sacramento
    Sanchez Salinas, Andres
    de la Rubia Nieto, Amelia
    Espuny Miro, Alberto
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2017, 23 (06) : 443 - 453
  • [42] Drug-drug interactions with oral anticoagulants: information consistency assessment of three commonly used online drug interactions databases in Switzerland
    Coumau, Claire
    Gaspar, Frederic
    Terrier, Jean
    Schulthess-Lisibach, Angela
    Lutters, Monika
    Le Pogam, Marie-Annick
    Csajka, Chantal
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [43] Evaluation of potential drug-drug interactions with medical cannabis
    Ho, Jessie Jia Yi
    Goh, Chenyi
    Leong, Caitlin Shen Ai
    Ng, Khuen Yen
    Bakhtiar, Athirah
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (05):
  • [44] Incidence of potential drug-drug interactions with antidiabetic drugs
    Samardzic, I.
    Bacic-Vrca, V.
    PHARMAZIE, 2015, 70 (06): : 410 - 415
  • [45] Use of metalloporphyrin catalyst(s) to evaluate biotransformations and potential drug-drug interactions
    Chapman, Chiara M.
    Jones, Graham B.
    Chorghade, Mukund S.
    Rahatgaonkar, Anjali M.
    Glick, James
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 247
  • [46] Evaluation of potential drug-drug interactions in a pediatric population
    Bebitoglu, Berna Terzioglu
    Oguz, Elif
    Nuhoglu, Cagatay
    Dalkilic, Ayse Ela Kurtdan
    Cirtlik, Pelin
    Temel, Fatime
    Hodzic, Ajla
    TURK PEDIATRI ARSIVI-TURKISH ARCHIVES OF PEDIATRICS, 2020, 55 (01): : 30 - 38
  • [47] Analysis of potential drug-drug interactions in hospitalized patients
    Wieczorek, M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (06) : 1550 - 1550
  • [48] Prevalence of potential drug-drug interactions in Slovenia in 2013
    Jazbar, Janja
    Locatelli, Igor
    Kos, Mitja
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2015, 37 (02) : 408 - 409
  • [49] Data mining for potential adverse drug-drug interactions
    Hammann, Felix
    Drewe, Juergen
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2014, 10 (05) : 665 - 671
  • [50] Clinical Pharmacokinetics of Cannabinoids and Potential Drug-Drug Interactions
    Vazquez, Marta
    Garcia-Carnelli, Carlos
    Maldonado, Cecilia
    Fagiolino, Pietro
    CANNABINOIDS AND SLEEP: MOLECULAR, FUNCTIONAL AND CLINICAL ASPECTS, 2021, 1297 : 27 - 42